Merus N.V. is a clinical-stage biotechnology company based in Utrecht, the Netherlands, with operations in the United States. The company develops full-length human bispecific and multispecific antibody therapeutics for oncology, using its proprietary Biclonics and Triclonics platforms to target solid tumors and hematologic malignancies. Merus is listed on Nasdaq under the ticker MRUS.
Key investigational programs include petosemtamab (MCLA-158), an EGFR x LGR5 bispecific antibody evaluated in head and neck and other solid tumors; zenocutuzumab (MCLA-128), a HER2/HER3 bispecific studied particularly in NRG1 fusion–positive cancers; MCLA-129, an EGFR x c-MET bispecific for EGFR- and MET-driven tumors; and MCLA-145, a CD137 x PD-L1 bispecific in immuno-oncology. The company advances these candidates through clinical development and scientific collaborations aimed at improving precision treatment options in cancer.
The report highlights 2025 achievements, financials, and 2026 outlook, including revenue growth, strategic acquisitions, and regulatory approvals.
Genmab adds petosemtamab to its portfolio, aiming for 2027 launch. Subsequent offer period open for remaining Merus shares.
Merus licenses Halozyme's ENHANZE® for subcutaneous petosemtamab, targeting solid tumors. Agreement includes upfront, milestone payments, and royalties.
Genmab will use proceeds from notes and loans to fund its Merus acquisition, with notes secured by assets and subject to covenants restricting debt and asset sales.
Revenue up 21% to $2.66B. Proposed Merus acquisition. FDA priority review for epcoritamab. Rina-S gets Breakthrough Therapy Designation. Operating profit rose to $1.007B.
Petosemtamab shows promising response rates in 1L and 2L mCRC, with potential as a new standard of care.
Petosemtamab shows antitumor activity and manageable safety in mCRC trials, with ongoing data updates to be presented at the conference.
Petosemtamab data in metastatic colorectal cancer to be presented in plenary and poster sessions at an upcoming conference.
